EUCTR2006-002472-17-FR进行中（未招募）1 期
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Genmab A/S
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy. - zalutumumab in non-curable patients with SCCHon-Curable Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-SEGenmab A/S273
进行中（未招募）
1 期
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy. - zalutumumab in non-curable patients with SCCHon-Curable Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-GBGenmab A/S273
进行中（未招募）
不适用
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy. - zalutumumab in non-curable patients with SCCHEUCTR2006-002472-17-EEGenmab A/S273
进行中（未招募）
1 期
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy.Ensayo abierto, aleatorizado, de grupos paralelos con zalutumumab , un anticuerpo monoclonal humano anti-receptor de EGF, en combinación con los mejores cuidados de soporte, frente a los mejores cuidados de soporte solamente, en pacientes con carcinoma escamoso de cabeza y cuello incurable que no han respondido a la quimioterapia estándar basada en platino. - zalutumumab in non-curable patients with SCCHCarcinoma escamoso de cabeza y cuello incurable Non-Curable Squamous Cell Carcinoma of the Head and NeckMedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-ESGenmab A/S273
进行中（未招募）
不适用
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy. - zalutumumab in non-curable patients with SCCHon-Curable Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-LTGenmab A/S273